IRBM

🔬 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗸𝗻𝗼𝘄𝘀 𝘁𝗵𝗮𝘁 𝗼𝗻𝗹𝘆 𝗮 𝗳𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗺𝗮𝗸𝗲 𝗶𝘁 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗼𝗳𝘁𝗲𝗻 𝗱𝘂𝗲 𝘁𝗼 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘀𝘁𝗮𝗴𝗲.   The key to success is 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗮𝗿𝗴𝗲𝘁 and working with a team that can expertly manage every step to identify a compound that 𝗰𝗮𝗻 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝘁𝗼 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗻𝗼𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻.   At IRBM our strength lies in our end-to-end approach, bringing together an exceptionally talented team of 60+ medicinal and peptide chemists co-located with target biology and pharmacology experts, all under one roof.   With decades of experience in 𝘀𝗺𝗮𝗹𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 and over 35 years of work in 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀, we are uniquely equipped to support your discovery program, ensuring your compound is thoroughly validated and poised for success as it approaches the pre-IND stage.   We’re excited to bring this expertise to the 𝗫𝗫𝗩𝗜𝗜𝗜 𝗘𝗙𝗠𝗖 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 from September 1-5, 2024, in Rome, Italy.   Our experts, including Alessia Petrocchi, Danila Branca, and Laura Mangiardi, will share insights on SHP2 inhibitors, peptide-based therapeutics, and compound management strategies. 🌟 A special mention goes to the 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗕𝗮𝗻𝗾𝘂𝗲𝘁 𝗼𝗻 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 4, at Villa Miani. This beautiful venue, offering stunning views of the eternal city, is the perfect setting for meaningful discussions about science and innovation.   We’re excited to connect with fellow experts and celebrate the future of medicinal chemistry. 🔔 Stay tuned for more updates!   #MedicinalChemistry #EFMCISMC2024 #DrugDiscovery #IRBM #ScientificResearch

Our journey as 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗱𝗿𝘂𝗴 𝗵𝘂𝗻𝘁𝗲𝗿𝘀 at IRBM has been shaped by the dedication and collaboration of our talented team. At the upcoming 37th European Peptide Symposium, you can meet Elisabetta Bianchi and Stefania Colarusso, who have been working together for many years to advance the field of peptide chemistry. During the Symposium: 📅 On August 27, Elisabetta Bianchi will present her work on "𝘾𝙝𝙚𝙢𝙞𝙘𝙖𝙡 𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙛 𝙇𝙖𝙘𝙩𝙖𝙢 𝘾𝙤𝙣𝙨𝙩𝙧𝙖𝙞𝙣𝙚𝙙 𝙈𝙖𝙘𝙧𝙤𝙘𝙮𝙘𝙡𝙚𝙨: 𝙊𝙧𝙖𝙡 𝙏𝙧𝙞𝙘𝙮𝙘𝙡𝙞𝙘 𝙋𝙚𝙥𝙩𝙞𝙙𝙚 𝙋𝘾𝙎𝙆9 𝙄𝙣𝙝𝙞𝙗𝙞𝙩𝙤𝙧𝙨 𝙛𝙤𝙧 𝙇𝘿𝙇-𝙇𝙤𝙬𝙚𝙧𝙞𝙣𝙜 𝙖𝙣𝙙 𝘾𝙤𝙧𝙤𝙣𝙖𝙧𝙮 𝙃𝙚𝙖𝙧𝙩 𝘿𝙞𝙨𝙚𝙖𝙨𝙚𝙨" 📅 On August 30, Stefania Colarusso will present "𝙊𝙪𝙧 𝙟𝙤𝙪𝙧𝙣𝙚𝙮 𝙖𝙨 𝙥𝙚𝙥𝙩𝙞𝙙𝙚 𝙙𝙧𝙪𝙜 𝙝𝙪𝙣𝙩𝙚𝙧𝙨 𝙖𝙩 𝙄𝙍𝘽𝙈" at the workshop “Navigating Entrepreneurship and Technology Transfer in Peptide Discovery and Development” Join us in supporting our 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗧𝗲𝗮𝗺 as they share the contributions they have made toward advancements in the field, and reach out to them, Sonia Del Rizzo, Martina Tripepi, Ali Hoseini, PhD, MBA, or Meg Sweeney if you’d like to meet at the symposium! #EPS2024 #IRBM #ScienceTalks

⚛️ At the 30th 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 𝗶𝗻 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 (#ICMRBS) in Seoul, we’re thrilled to be among the top researchers exploring the advancements in magnetic resonance within biological systems. It’s a unique opportunity to engage with leading experts shaping the future of this field. We’re passionate about how 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 (NMR) technology drives innovation in drug discovery by offering unparalleled precision in structural biology. Leveraging advanced NMR, at IRBM we provide deep insights into molecular interactions, enabling the identification and optimization of lead compounds with high affinity and selectivity. 👉 Our poster on the "Discovery of a novel HTT ligand with preferential binding to polyQ expanded HTT Exon1", a study performed in collaboration with CHDI Foundation, sparked meaningful discussions, showcasing the critical role NMR plays in ligand discovery and characterization. We’re looking forward to continued exchanges with the community and new collaborations in pushing the boundaries of drug discovery. Alessandro Piai Michele Luche #ICMRBS2024 #StructuralBiology #NMR #DrugDiscovery #IRBM #Biotech

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 🧪🔬 As we gear up for the 37th European Peptide Symposium, hosted by Professors Anna Maria Papini and Paolo Rovero in the beautiful city of Florence, Italy, we're excited to continue driving forward the future of 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 alongside fellow experts. And we're proud to have two of our brilliant peptide scientists contributing to the dialogue: 📅 Elisabetta Bianchi will present "𝘾𝙝𝙚𝙢𝙞𝙘𝙖𝙡 𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙛 𝙇𝙖𝙘𝙩𝙖𝙢 𝘾𝙤𝙣𝙨𝙩𝙧𝙖𝙞𝙣𝙚𝙙 𝙈𝙖𝙘𝙧𝙤𝙘𝙮𝙘𝙡𝙚𝙨: 𝙊𝙧𝙖𝙡 𝙏𝙧𝙞𝙘𝙮𝙘𝙡𝙞𝙘 𝙋𝙚𝙥𝙩𝙞𝙙𝙚 𝙋𝘾𝙎𝙆9 𝙄𝙣𝙝𝙞𝙗𝙞𝙩𝙤𝙧𝙨 𝙛𝙤𝙧 𝙇𝘿𝙇-𝙇𝙤𝙬𝙚𝙧𝙞𝙣𝙜 𝙖𝙣𝙙 𝘾𝙤𝙧𝙤𝙣𝙖𝙧𝙮 𝙃𝙚𝙖𝙧𝙩 𝘿𝙞𝙨𝙚𝙖𝙨𝙚𝙨" on August 27. 📅 Stefania Colarusso will present "𝙊𝙪𝙧 𝙟𝙤𝙪𝙧𝙣𝙚𝙮 𝙖𝙨 𝙥𝙚𝙥𝙩𝙞𝙙𝙚 𝙙𝙧𝙪𝙜 𝙝𝙪𝙣𝙩𝙚𝙧𝙨 𝙖𝙩 𝙄𝙍𝘽𝙈" at the workshop on August 30. Running from August 25th to 29th, 2024, the symposium promises a captivating program covering the latest advancements in peptide research and applications. Satellite workshops will be held on August 30th and 31st, offering additional opportunities for deep dives into specialized topics. Join us as we delve into the potential of peptides in addressing some of today's most pressing medical challenges. Elisabetta Bianchi Stefania Colarusso Martina Tripepi Sonia Del Rizzo Ali Hoseini, PhD, MBA Meg Sweeney   🔬#EPS2024 #PeptideTherapeutics #DrugDiscovery #MedicalInnovation #IRBM

The healthcare sector is responsible for approximately 5% of all global greenhouse gas emissions, with laboratories found to consume 5-10X more energy than typical office spaces. But 𝗶𝗻𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻𝘁𝗼 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗶𝘀 𝗴𝗮𝗶𝗻𝗶𝗻𝗴 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺, as illustrated by the many green initiatives being implemented across the globe. As evidenced by our recent 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗚𝗼𝗹𝗱 𝗿𝗮𝘁𝗶𝗻𝗴, IRBM, like many life sciences organizations, is 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗼𝘂𝗿 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗳𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁 and showcasing practical steps toward more sustainable research methodologies. We are hopeful for the future, but also realize that these initiatives are often challenging to implement due to cost and logistical barriers, so how important is sustainability when planning your drug discovery programs? #IRBMpolls #IRBM #drugdiscovery #greeninitiatives

𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 (NMR) spectroscopy accelerates drug discovery by providing precise structural insights into molecular interactions, enabling rapid identification and optimization of lead compounds with high binding affinities and selectivity. And IRBM is heading to Seoul for the 30th International Conference on Magnetic Resonance in Biological Systems (ICMRBS)! Join our brilliant team members, Alessandro Piai and Michele Luche, as we journey into the future of NMR. Why should you connect with us at #ICMRBS2024? 🚀 Discover how our NMR technologies can advance your discovery programs. 🔬 Engage with our experts to ignite innovative collaborations.   Let’s come together to push the boundaries of what’s possible in structural biology. See you there! #ICMRBS #structuralbiology #NMR #DrugDiscovery #IRBM #Biotech

With false claims and “ESG washing” being all too common, how can you be sure that a company is genuinely committed to sustainability? The IRBM Group’s recent 𝗚𝗼𝗹𝗱 𝗿𝗮𝘁𝗶𝗻𝗴 and performance evaluation from globally-trusted EcoVadis revealed: // We’re in the 𝘁𝗼𝗽 𝟱% of all companies rated by EcoVadis // We reached the 𝘁𝗼𝗽 𝟮% among scientific R&D companies! // We’re among the 𝘁𝗼𝗽 𝟭% in the category of Labor & Human Rights! These achievements reflect our team’s hard work in 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗶𝗻𝗴 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹, 𝘀𝗼𝗰𝗶𝗮𝗹, 𝗮𝗻𝗱 𝗲𝘁𝗵𝗶𝗰𝗮𝗹 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀, which can be trusted and truly make a difference. 🡺 Why This Matters: // 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: Collaborating with IRBM means supporting significant environmental change. Companies with strong environmental policies can reduce their carbon emissions by up to 58% more than those without (Journal of Sustainable Finance & Investment). // 𝗘𝘁𝗵𝗶𝗰𝗮𝗹 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀: Our commitment to ESG standards ensures ethical and responsible business conduct, fostering trust throughout every project. // 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽: Partnering with IRBM means working with a recognized sustainability leader, ensuring your projects meet and set industry standards. Join us and be a 𝗰𝗮𝘁𝗮𝗹𝘆𝘀𝘁 𝗳𝗼𝗿 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗰𝗵𝗮𝗻𝗴𝗲. Keep pushing for robust ESG practices within your own organization and 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝘄𝗶𝘁𝗵 𝘂𝘀 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗻𝗲𝘅𝘁 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 to drive a sustainable future together. 📸: Emanuela Scarpa, Claudia Penati, Monica Polsinelli, Raffaella Mancini, Valentina Gallo (While only some of the key project team members are captured in this photo, we’d like to thank all who participated in gathering the data required to achieve this important rating!) Advaxia Biologics #IRBM #Sustainability #EcoVadis #ESG #Biotech #Pharma

What if the next breakthrough in cancer treatment could be accelerated by strategic partnerships? At IRBM, one of our key focuses is the advancement of immune-oncology drug discovery programs. Our achievements include contributions to the development of ZEJULA®, an approved therapy for ovarian cancer. With deep expertise in oncology drug discovery and translational research, our team has advanced numerous clinical candidates into trials.   This is why we look forward to participating in the IMMUNO-ONCOLOGY SUMMIT 2024 in Philadelphia. This summit offers a prime opportunity to explore the latest in emerging targeting technologies, personalized immunotherapy, cell-based immunotherapies, and strategies to overcome tumor resistance.   Join us and meet our brilliant team: Giulio Auciello, Betsy McKibben, and Kaile W., to explore how we can support your oncology pipeline.   See you in Philly for an inspiring and productive summit! #IOSummit #Immunooncology #CancerResearch #DrugDiscovery #IRBM

𝗛𝗶𝗴𝗵-𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗰𝗲𝗹𝗹 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 is crucial in drug discovery, enabling detailed analysis of cellular responses. Integrating seamlessly with genomics, proteomics, and computational biology, it enhances the precision and efficiency of progression through the discovery pipeline, 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗥&𝗗 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀. IRBM’s 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗶𝗻 𝗵𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝗺𝗶𝗰𝗿𝗼𝘀𝗰𝗼𝗽𝘆 combined with the innovative imaging system of the Opera Phenix® Plus enables 𝗿𝗮𝗽𝗶𝗱 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗹𝗲𝗮𝗱 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀 and the elucidation of their 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗼𝗳 𝗮𝗰𝘁𝗶𝗼𝗻. In addition to our ability to produce ad hoc, project-specific assays, some of our optimized assays include: // Antibody and Peptide Internalization // Spheroid Assays // Protein Localization // Neurite Outgrowth // Autophagy // Live Tracking // DNA Damage // Cell Cycle Analysis // Apoptosis and Cytotoxicity Supported by an expert team, high-content analysis software, and a 3D viewer, we can retrieve large amounts of data, perform complex analyses, and examine 3D cell models in both fixed and live cells, facilitating the interpretation of screening results and 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗽𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗲𝘀. Get in touch via the comments or a direct message to find out more about our cell imaging facility and how we can empower your drug discovery project. 📸 Our experts: Chiara Soldati, Valeria Colicchia, Sara Pugliese #cellimaging #highcontentscreening #drugdiscovery #IRBM

𝗪𝗮𝗻𝘁 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗶𝗺𝗽𝗮𝗰𝘁 𝗶𝗻 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗵𝗶𝗹𝗲 𝗲𝗻𝗷𝗼𝘆𝗶𝗻𝗴 𝘁𝗵𝗲 𝗯𝗲𝗮𝘂𝘁𝘆 𝗼𝗳 𝗜𝘁𝗮𝗹𝘆? 🇮🇹🌍 Join IRBM and benefit from cutting-edge facilities, collaborative international projects, and a vibrant work-life balance in one of the most inspiring countries. Ready to bring your expertise back home? #researchopportunity #IRBM #scientificexcellence #drugdiscovery #rientrodeicervelli